BIBF 1120 for the treatment of non-small cell lung cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   Google Scholar
• Molina JR, Yang P, Cassivi SD, Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83(5):584-94
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095-103
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-97
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372(9652):1809-18
   PubMed Web of Science ®Google Scholar
• Quesada AR, Medina MA, Alba E. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays 2007;29(11):1159-68
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-4
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-8
   PubMed Web of Science ®Google Scholar
• Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition–a critical review. Anticancer Agents Med Chem 2007;7(2):223-45
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10
   PubMed Web of Science ®Google Scholar
• Shojaei F, Ferrara N. Antiangiogenic therapy for cancer: an update. Cancer J 2007;13(6):345-8
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131(6):1190-203
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10(2):116-29
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL. J Clin Oncol 2009;27(8):1227-34
   PubMed Web of Science ®Google Scholar
• Novello S, Scagliotti GV, Rosell R, Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101(9):1543-8
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von Pawel J, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42
   Google Scholar
• Hilberg F, Roth GJ, Krssak M, BIBF1120: Triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacy. Cancer Res 2008;68(12):4774-82
   PubMed Web of Science ®Google Scholar
• Hilberg F, Brandstetter I, Roth GJ. In vitro and in vivo efficacy of BIBF 1120, a small molecule triple angiokinase inhibitor, in combination with taxanes. Proceedings AACR-NCI-EORTC. Int Conf Mol Targets Cancer Ther 2005;59:A19
   Google Scholar
• Stopfer P, Roth W, Mross KB, Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients. Eur J Cancer Suppl 2006;4(12):26
   Web of Science ®Google Scholar
• Mross K, Stefanic M, Gmehling D, Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16(1):311-9
   PubMed Web of Science ®Google Scholar
• Lee CP, Taylor NJ, Attard G, A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol 2006;24(18S):3015
   Google Scholar
• Kaneda H, Okamoto I, Satoh T, Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumours (and presentation). Eur J Cancer Suppl 2009;7(2): abstract 1243
   Google Scholar
• Camidge DR, Conkling P, Stephenson J, Shapiro D. A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Thoracic Oncol 2007;2(8):S730
   Google Scholar
• Hanna N, Ellis P, Stopfer P, A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer. J Thoracic Oncol 2007;2(8):S717
   Google Scholar
• von Pawel J, Kaiser R, Eschbach C, Efficacy, safety and pharmacokinetic (PK) results of a Phase II study with the triple angiokinase inhibitor BIBF 1120 in patients suffering from advanced non small cell lung cancer (NSCLC). J Thoracic Oncol 2008;3(4):S61
   Google Scholar
• LUME-Lung 1: BIBF 1120 plus docetaxel as compared to placebo plus docetaxel in 2nd line NSCLC. ClinicalTrialsgov 2008; LUME-Lung 1 study. Available from: http://clinicaltrials.gov/ct2/show/NCT00805194?term=BIBF+ 1120&rank=6. [Cited 15 April 2009]
   Google Scholar
• LUME-Lung 2: BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC. ClinicalTrialsgov 2008; LUME-Lung 2 study. Available from: http://clinicaltrials.gov/ct2/show/NCT00806819?term=BIBF+1120&rank=4. [Cited 15 April 2009]
   Google Scholar
• Roth GJ, Heckel A, Colbatzky F, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009;52(14):4466-80
   PubMed Web of Science ®Google Scholar